Key takeaways
Dupixent (dupilumab) and Xolair (omalizumab) are both injectable medications used to treat various inflammatory and allergic conditions, but they work differently and have different uses. Dupixent (dupilumab) is a monoclonal antibody that blocks proteins responsible for inflammation, making it effective for conditions like eczema, asthma, and sinus congestion with nasal polyps. It is typically injected every other week or monthly. Xolair (omalizumab), on the other hand, targets immunoglobulin E (IgE) to prevent allergic reactions and is used for allergic asthma, chronic hives, and nasal polyps. It is usually injected every 2 or 4 weeks. While Dupixent (dupilumab) is available only as a brand-name medication, Xolair (omalizumab) also does not have a generic form. Common side effects of Dupixent include injection site reactions and eye inflammation, whereas Xolair can cause headaches, stomach pain, and dizziness. Additionally, Xolair has a risk of severe allergic reactions, which is less common with Dupixent.
